Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q2 EPS
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $1.15 million versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.